Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 49

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Non-small cell lung cancer stage I

Not yet recruiting

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Acute respiratory distress syndrome

Not yet recruiting

Study on Premedication with Ketamine or Fentanyl for Patients with Respiratory Distress Syndrome Receiving Surfactant Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Fentanyl Citrate
  • Sponsor:Pohjois-Pohjanmaan hyvinvointialue

Acute respiratory distress syndrome

Not yet recruiting

Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Ospedale San Raffaele S.r.l.

Non-small cell lung cancer stage IIIA+1

Not yet recruiting

Study on Pembrolizumab as Maintenance Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer After Chemo-Radiotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Universita' Degli Studi Di Torino

Non-small cell lung cancer

Not yet recruiting

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacomitinib
  • Sponsor:Fondazione Ricerca Traslazionale

Renal cell carcinoma+2

Not yet recruiting

Study on the Safety and Effectiveness of AL8326 for Patients with Small Cell Lung Cancer Needing Second-Line Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AL8326
  • Sponsor:Advenchen Pharmaceuticals LLC

Asthma

Not yet recruiting

Study on Adjusting Omalizumab Dosage for Patients with Severe Allergic Asthma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Consorci Mar Parc De Salut De Barcelona

Non-small cell lung cancer stage III

Not yet recruiting

Study on Durvalumab and Chemotherapy for Patients with Relapsed Stage III Non-Small Cell Lung Cancer After Chemoradiotherapy and Durvalumab Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione Ricerca Traslazionale

Pulmonary embolism

Not yet recruiting

Study on Lung Function After Pulmonary Embolism Using Galligas and 68Ga-MAA in Patients with Pulmonary Embolism

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Graphite
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Rhinitis allergic+1

Not yet recruiting

Evaluation of Alutard SQ dog allergen immunotherapy in patients with allergic rhinitis due to dog allergy - A one-year study in Swedish practice

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Desloratadine
  • Sponsor:Karolinska Institutet

Dyspnoea

Not yet recruiting

Study on Fentanyl and Morphine for Treating Severe Shortness of Breath in Heart Failure Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Fentanyl
  • Sponsor:Fundacio Assistencial De Mutua De Terrassa Fpc

Non-small cell lung cancer stage III

Not yet recruiting

Study on Alectinib for Patients with ALK+ Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.